2438-38-2

Basic information

• Product Name: Cyclohexanesulfonamide(7CI,8CI,9CI)
• Synonyms: Cyclohexanesulfonamide(7CI,8CI,9CI);Cyclohexanesulfonamide;NSC 516369;NSC 516377
• CAS NO: 2438-38-2
• Molecular Formula: C₆H₁₃NO₂S
• Molecular Weight: 163.24
• Product Categories: SULFONAMIDE
• Mol File: 2438-38-2.mol
• Article Data: 27

Chemical Properties

• Melting Point: 94-95℃
• Boiling Point: 299.8°Cat760mmHg
• Flash Point: 135.1°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 0.00116mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.58±0.20(Predicted)
• CAS DataBase Reference: Cyclohexanesulfonamide(7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanesulfonamide(7CI,8CI,9CI)(2438-38-2)
• EPA Substance Registry System: Cyclohexanesulfonamide(7CI,8CI,9CI)(2438-38-2)

Safety Data

• Hazardous Substances Data: 2438-38-2(Hazardous Substances Data)

Usage

General Description

Cyclohexanesulfonamide, also known as cyclohexylsulfamic acid, is a chemical compound with the molecular formula C6H13NO2S. It is a white crystalline solid that is commonly used as a corrosion inhibitor in industrial water treatment processes. Cyclohexanesulfonamide is also used as a plasticizer and as an intermediate in the production of pharmaceuticals and agrochemicals. It is known to be toxic to aquatic organisms and may cause long-term adverse effects in the aquatic environment. Additionally, it is considered to be a mild irritant to the skin, eyes, and respiratory system, and should be handled and disposed of with care to avoid potential harm to human health and the environment.

InChI:InChI=1/C6H13NO2S/c7-10(8,9)6-4-2-1-3-5-6/h6H,1-5H2,(H2,7,8,9)

Upstream product

• 2387-23-7 1,3-Dicyclohexylurea 
• 7664-41-7 ammonia 
• 4837-38-1 cyclohexanesulfonyl chloride 
• 1569-69-3 Cyclohexanethiol 
• 88304-20-5 isobutylidene-cyclohexylamine 

Downstream Products

• 3321-29-7 N-butyl-N'-cyclohexanesulfonyl-urea 
• 1610042-45-9 N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-cyclohexanesulfonamide 
• 1610042-54-0 N-(3-((3,5-dimethylphenyl)amino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cyclohexanesulfonamide 
• 1609109-60-5 C₃₄H₄₈N₄O₅S 
• 926299-66-3 N-(cyclohexylsulfonyl)-3-[1-(2,4-dichlorobenzyl)-3-isopropoxy-1H-pyrazol-5-yl]propanamide 
• 90729-21-8 N-ethyl-N'-cyclohexanesulfonyl-urea 
• 99066-09-8 cyclohexanesulfonyl-carbamic acid ethyl ester 
• 98428-73-0 cyclohexanesulfonyl-urea 

Relevant articles and documents

NEW BRAF INHIBITORS AS PARADOX BREAKERS

The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators

Exchange proteins directly activated by cAMP (EPAC) play a central role in various biological functions, and activation of the EPAC1 protein has shown potential benefits for the treatment of various human diseases. Herein, we report the synthesis and biochemical evaluation of a series of noncyclic nucleotide EPAC1 activators. Several potent EPAC1 binders were identified including 25g, 25q, 25n, 25u, 25e, and 25f, which promote EPAC1 guanine nucleotide exchange factor activity in vitro. These agonists can also activate EPAC1 protein in cells, where they exhibit excellent selectivity toward EPAC over protein kinase A and G protein-coupled receptors. Moreover, 25e, 25f, 25n, and 25u exhibited improved selectivity toward activation of EPAC1 over EPAC2 in cells. Of these, 25u was found to robustly inhibit IL-6-activated signal transducer and activator of transcription 3 (STAT3) and subsequent induction of the pro-inflammatory vascular cell adhesion molecule 1 (VCAM1) cell-adhesion protein. These novel EPAC1 activators may therefore act as useful pharmacological tools for elucidation of EPAC function and promising drug leads for the treatment of relevant human diseases.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.